Steven J. Potts
Oprichter bij Oncomyx Therapeutics, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Sandra E. Dunn | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 12 jaar |
Michael Wood | M | - |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
Aarthi Jayanthan | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 9 jaar |
Janet Grove | F | 57 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Julia G. Levy | M | 89 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Magda Marquet | M | 65 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 5 jaar |
Charles Baum | M | 65 |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | 4 jaar |
Christopher Bissonnette | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 6 jaar |
Lana Janes | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
David A. Schellenberg | M | 60 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Alan Ashworth | M | 63 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Jason Rushton | M | 54 |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
Kanad D. Das | M | - |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
Tim Xiao | M | 37 |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
Robert Levak | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 3 jaar |
Widya Mulyasasmita | M | - |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Canada | 10 | 62.50% |
Verenigde Staten | 6 | 37.50% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Steven J. Potts
- Persoonlijk netwerk